OBJECTIVES: This study aimed to evaluate the cost-effectiveness of dabigatran compared to acenocoumarol, rivaroxaban and apixaban, for thromboembolic events prevention in atrial fibrillation patients.

METHODS: The population was modeled using a Markov cohort model that describes the natural history of a patient with AF in terms of the consequences derived from the occurrence of ischemic/hemorrhagic events. Regarding the occurrence of major events, two major sources were used to populate the model: the RE-LY trial and the network meta-analysis (NMA) published by Lopez-Lopez et al. Direct costs measured as Chilean pesos (1 USD = 710.9 CLP) were obtained from local tariff sources, whereas utilities were obtained from the literature. Deterministic and Probabilistic sensitive analysis were performed. An additional scenario-analysis explored the use of Idarucizumab and prothrombin-complexes-concentrate (PCC) as reversal agents in an emergency setting.